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Abstract 
In contrast to the upfront setting in which the role of high-dose therapy with autologous 
hematopoietic cell transplantation (HCT) as consolidation of a first remission in patients with 
multiple myeloma (MM) is well established, the role of high-dose therapy with autologous or 
allogeneic HCT has not been extensively studied in MM patients relapsing after primary therapy. 
The International Myeloma Working Group together with the Blood and Marrow Transplant 
Clinical Trials Network, the American Society of Blood and Marrow Transplantation, and the 
European Society of Blood and Marrow Transplantation convened a meeting of MM experts to: (1) 
summarize current knowledge regarding the role of autologous or allogeneic HCT in MM patients 
progressing after primary therapy, (2) propose guidelines for the use of salvage HCT in MM, 
(3) identify knowledge gaps, (4) propose a research agenda, and (5) develop a collaborative 
initiative to move the research agenda forward. After reviewing the available data, the expert 
committee came to the following consensus statement for salvage autologous HCT: (1) In 
transplantation-eligible patients relapsing after primary therapy that did NOT include an autologous 
HCT, high-dose therapy with HCT as part of salvage therapy should be considered standard; (2) 
High-dose therapy and autologous HCT should be considered appropriate therapy for any patients 
relapsing after primary therapy that includes an autologous HCT with initial remission duration of 
more than 18 months; (3) High-dose therapy and autologous HCT can be used as a bridging strategy 
to allogeneic HCT; (4) The role of postsalvage HCT maintenance needs to be explored in the 
context of well-designed prospective trials that should include new agents, such as monoclonal 
antibodies, immune-modulating agents, and oral proteasome inhibitors; (5) Autologous HCT 
consolidation should be explored as a strategy to develop novel conditioning regimens or post-HCT 
strategies in patients with short (less than 18 months remissions) after primary therapy; and (6) 
Prospective randomized trials need to be performed to define the role of salvage autologous HCT in 
patients with MM relapsing after primary therapy comparing it to “best non-HCT” therapy. The 
expert committee also underscored the importance of collecting enough hematopoietic stem cells to 
perform 2 transplantations early in the course of the disease. Regarding allogeneic HCT, the expert 
committee agreed on the following consensus statements: (1) Allogeneic HCT should be considered 
appropriate therapy for any eligible patient with early relapse (less than 24 months) after primary 
therapy that included an autologous HCT and/or high-risk features (ie, cytogenetics, extramedullary 
disease, plasma cell leukemia, or high lactate dehydrogenase); (2) Allogeneic HCT should be 
performed in the context of a clinical trial if possible; (3) The role of postallogeneic HCT 
maintenance therapy needs to be explored in the context of well-designed prospective trials; and (4) 
Prospective randomized trials need to be performed to define the role salvage allogeneic HCT in 
patients with MM relapsing after primary therapy. 
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Introduction 
Multiple myeloma (MM) is a disease characterized by malignant plasma cell proliferation, bone 
destruction, and immunodeficiency. The median age at diagnosis is approximately 70 years. MM is 
responsible for about 1% of all cancer-related deaths in western countries [1]. 
Modern therapy now includes induction therapy with combinations of immune-modulatory drugs 
(IMiDs), such as thalidomide and lenalidomide, and proteasome inhibitors (bortezomib and 
carfilzomib) in combination with steroids, alkylators, or anthracyclines. When possible, patients 
who are deemed “transplantation eligible” undergo consolidation therapy with high-dose melphalan 
and autologous hematopoietic cell transplantation (HCT). This therapeutic strategy has improved 
the median overall survival (OS) for patients with MM from 36 months to more than 5 years in 
patients with standard risk MM 2, 3 and 4. 
Despite modern therapy, most patients with MM will live to see their disease recur. Several 
prognostic factors for disease progression have been identified, such as beta-2 micro-globulin, 
albumin (International Staging System [ISS] score), plasma cell labeling index, elevated serum 
lactate dehydrogenase, and certain chromosomal abnormalities, such as t(4;14) and t(14;16), either 
partial or complete deletion of chromosome 17, deletion of 8q21, and 1p loss or 1q gains 5, 6, 7, 
8 and 9. 
The availability of both proteasome inhibitors and IMiDs has led to the development of multiple 
combination chemotherapy regimens as salvage therapies that include different permutations of 
these drugs. Although response rates of the combinations are higher, it is uncertain whether any 
specific combination is associated with better survival or whether sequential therapy would be 
equally effective [10]. 
These new combinations have resulted in dramatic OS improvements for MM patients relapsing 
after primary therapy over the last decade. The magnitude of improvement was examined by Kumar 
et al. The median OS after relapse increased from 11.8 months for patients relapsing before 2000 to 
24 months for patients relapsing beyond that date. The OS benefit was seen primarily in patients 
receiving 1 of the IMiDs or proteasome inhibitors. The prognosis for patients who become resistant 
to both agents is extremely poor. Among 286 patients identified, 74% received subsequent therapy 
(range, 0 to 8), with 44% of patients achieving at least a minor response. The median OS and event-
free survival from the time of registration were 9 and 5 months, respectively. These patients have 
been successfully treated with novel therapeutic approaches, including carfilzomib and/or 
pomalidomide, but will invariably succumb to their disease 10, 11 and 12. 
In contrast to the upfront setting, in which the role of high-dose therapy as consolidation of a first 
remission is well established, the role of a second course of high-dose therapy with autologous or 
allogeneic HCT has not been extensively studied. To that effect, the International Myeloma 
Foundation through its International Myeloma Working Group, together with the Blood and 
Marrow Transplant Clinical Trials Network, the National Marrow Donor Program, the European 
Society of Blood and Marrow Transplantation (EBMT), and the American Society of Blood and 
Marrow Transplantation, convened a meeting of MM experts regarding the role of autologous or 
allogeneic HCT in the treatment of patients who had progressed after primary therapy with or 
without autologous HCT consolidation. The goals of the meeting were as follows: 
•Summarize current knowledge regarding the role of autologous or allogeneic HCT in MM patients 
progressing after primary therapy 
•Propose guidelines for the use of salvage HCT in MM 
•Identify knowledge gaps 
•Propose a research agenda 
•Develop a collaborative initiative to move the research agenda forward 
Herein are the results of those deliberations held in Minnesota on October 27, 2014. The meeting 
was supported in part by an unrestricted grant from Sanofi Pharmaceuticals to the International 
Myeloma Foundation and from the BMT CTN U01. 
Current Standards for Treatment of Relapsed and/or 
Refractory Myeloma 
Before the advent of IMiDs and proteasome inhibitors, patients with relapsed MM had limited 
therapeutic options. Salvage therapy with alkylators, anthracycline, steroids, vinca alkaloids, or 
combinations had response rates of 50% or less with short remission durations and poor prognoses 
13 and 14. Salvage therapy for MM has been greatly improved by the availability of new agents and 
combinations. Table 1 summarizes the most relevant phase II trials exploring new combinations of 
IMiDs and proteasome inhibitors in patients with relapsed and or refractory MM. 
 
 
 
 
 
 
 
 
 
Table 1. Phase II Trials of New Combination Therapies for Relapsed and Refractory 
Myeloma 
 
 
Ref indicates reference; ORR, overall response rate; Thal, thalidomide; Dex, dexamethasone; 
RRMM, relapse/refractory multiple myeloma; Len, lenalidomide; Pom, pomalidomide; Bor, 
bortezomib; PegAnthr, pegylated anthracycline; NS, not stated; Car, carfilzomib; VTD, bortezomib, 
thalidomide, dexamethasone; RVD, lenalidomide, bortezomib, dexamethasone; CyBor, 
cyclophosphamide, bortezomib; KRD, carfilzomib, lenalidomide, dexamethasone; Elo, elotuzumab; 
NR, not reached. 
In the last 2 years, 4 randomized trials have been performed and reported assessing optimal 
treatment of patients relapsing after 1 to 3 prior lines of treatment. The first trial was reported by 
Garderet et al. and compared the efficacy and safety of bortezomib-thalidomide-dexamethasone 
versus thalidomide-dexamethasone in patients relapsing after an autologous HCT. A total of 269 
patients were randomized. Complete remission (CR) and near CR rates were significantly better for 
bortezomib-thalidomide-dexamethasone than for thalidomide-dexamethasone (45% versus 25%), 
which translated into an superior median time to progression (19.5 versus 13.8 months) and a trend 
towards improved 24-month survival (71% versus 65%; P = .093). Grade 3 neuropathy and grades 
3 and 4 infection and thrombocytopenia were significantly higher in the bortezomib-thalidomide-
dexamethasone arm [28]. 
Stewart et al. reported the results of a randomized trial of carfilzomib, lenalidomide, and 
dexamethasone versus lenalidomide and dexamethasone in patients with MM failing 1 to 3 prior 
therapies (ASPIRE Trial). ASPIRE enrolled 792 patients with relapsed or refractory MM. The 
objective response rate was 87% for carfilzomib, lenalidomide, and dexamethasone versus 67% for 
lenalidomide and dexamethasone, with a significantly higher rate of CRs in the carfilzomib, 
lenalidomide, and dexamethasone arm (32% versus 9%; P < .0001). Median progression-free 
survival (PFS) in the carfilzomib, lenalidomide, and dexamethasone arm was 26.3 months versus 
17.6 months for the lenalidomide and dexamethasone arm. Median OS has not been reached in 
either group, but there was a trend toward longer survival in the carfilzomib arm [29]. 
San Miguel et al. reported the results of a phase III trial comparing panobinostat, bortezomib, and 
dexamethasone to bortezomib and dexamethasone in patients with MM failing 1 to 3 prior 
therapies. Of 768 randomized patients, 387 received panobinostat, bortezomib, and dexamethasone 
and 382 received placebo, bortezomib, and dexamethasone. Panobinostat, bortezomib, and 
dexamethasone showed superior PFS when compared with placebo, bortezomib, and 
dexamethasone (12.0 versus 8.1 months; hazard ratio, .63; P < .0001) with no OS difference 
reported. Complete plus near complete response rates were 28% and 16%, with median response 
duration of 13.1 and 10.9 months, respectively [30]. 
Lonial et al. reported the results of a phase III trial comparing the combination of elotuzumab plus 
lenalidomide plus dexamethasone to placebo plus lenalidomide plus dexamethasone (Eloquent 2) 
[31]. Overall, 321 patients were assigned to the elotuzumab group and 325 to the control group. 
After a median follow-up of 24.5 months, the rate of PFS at 1 year in the elotuzumab group was 
68% compared with 57% in the control group; at 2 years, the rates were 41% and 27%, respectively. 
Median PFS in the elotuzumab group was 19.4 months versus 14.9 months in the control group 
(hazard ratio for progression or death in the elotuzumab group, .70; 95% confidence interval, .57 to 
.85; P < .001). 
Therefore, by the end of 2015, the MM community has completed 4 randomized trials in patients 
with relapsed MM (failing 1 to 3 prior therapies) in which all of those reported to date have 
demonstrated that more intense therapy (triplets versus doublets) is associated with improvements 
in depth of response, and that depth of response is associated with improvements in PFS although a 
definitive survival benefit has not been shown. These results are summarized in Table 2. 
Table 2. Results of Phase III Trials Comparing Two to Three Drug Combinations in 
Patients with Myeloma Failing One to Three Prior Therapies 
 
 
TD indicates thalidomide, dexamethasone; RD, lenalidomide, dexamethasone; Pano Bor Dex, panobinostat, 
bortezomib, dexamethasone; Bor Dex, bortezomib, dexamethasone; Rev Dex, lenalidomide, 
dexamethasone. 
With the increasing efficacy of salvage therapy for MM, the role of high-dose therapy with HCT 
support (so-called salvage HCT) to further enhance the depth of response is being increasingly 
explored and formed the basis of discussion for the expert committee. 
What is the Definition of Salvage HCT? 
For the purpose of discussion, the expert committee defined salvage HCT as either an autologous or 
allogeneic HCT performed on MM patients who had failed a prior line of therapy. The committee 
recognized that this definition would encompass multiple scenarios, ranging from transplantation-
naïve patients failing frontline treatment to patients who had failed multiple therapies without ever 
having an HCT. 
Role of Autologous HCT as Treatment for Patients Relapsing 
after Primary Therapy in Transplantation-Naïve Patients 
The optimal treatment for transplantation-eligible patients who relapsed after an initial therapy that 
did not include high-dose therapy consolidation remains uncertain, although it is the comparator 
arm for all randomized trials of early versus delayed HCT. Reinduction treatment with combination 
chemotherapy is the standard and most experts agreed that high-dose therapy consolidation should 
be considered the standard of care at this time for this patient population. The expert committee 
agreed that this patient population, although heterogeneous, is worthy of prospective trials designed 
to address the issue of optimal reinduction therapy and consolidation to determine whether their 
natural history is different than that for patients relapsing after a prior autograft. 
Role of Autologous HCT for Patients Relapsing after Prior 
Autograft 
Retrospective Trials 
To date, multiple reports of salvage autologous HCT have been published and are summarized in 
Table 3. In all reports, chemosensitivity and remission duration after first autograft were the most 
important prognostic factors for subsequent long-term disease control. However, it is still uncertain 
whether all patients would benefit from salvage autograft regardless of remission duration. Most 
reports identified that the number of lines of prior therapy had a significant impact on outcomes and 
suggested that salvage autologous HCT should not be relegated to a “last-ditch effort” in patients 
who have failed all prior therapies, but it should be considered an integral component of initial 
salvage strategies. Of particular importance is the retrospective analysis performed by Grövdal et al. 
in which treatment outcomes of 1061 consecutive patients from 24 hospitals in Denmark, Finland, 
Norway, and Sweden who had received an autologous HCT as consolidation of a first remission 
were reported. During the study period, 564 patients progressed and were treated with either 
conventional chemotherapy (n = 91); IMiDs and/or proteasome inhibitors (n = 362), or a second 
autologous HCT after either approach (n = 111). Patients who received salvage therapy that 
included a second HCT had a statistically significantly longer median survival; 4 years compared 
with 3.3 years for those who received salvage therapy with IMiDs and/or proteasome inhibitors but 
without a second autologous HCT and 2.5 years for those who received conventional 
chemotherapy. Of note, in this analysis, even patients undergoing a second autograft with initial 
remission durations of less than 12 months still benefited from the procedure when compared with 
the other groups [41]. 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Retrospective Analysis of Salvage Autologous HCT Outcomes (Series with 
More Than 40 Patients) 
 
RD indicates remission duration; VGPR, very good partial response. 
 
Current Activity in North America 
Data from the Center for International Blood and Marrow Transplant Research (CIBMTR) data 
base show that since 1995, 22,069 MM patients were reported to have relapsed after autologous 
HCT. Data regarding salvage HCT were available on 80% of relapsed patients: most of them 
(15,529 [87%]) did not receive a subsequent HCT, 1606 (9%) received another autologous HCT 
(mostly single, 1524 [85%] or rarely a tandem, 82 [<1%]). Another 624 patients (3.6%) underwent 
an allogeneic HCT at some point during their treatment course as salvage therapy. However, since 
2001, there is a constant increase in the salvage HCT activity, with more than 300 patients per year 
after 2010 (Figure 1A,B). 
 
 Figure 1. (A) Number or salvage HCT performed for MM in North America over time (CIBMTR 
registry). (B) Type of salvage HCT performed for MM over time (CIBMTR registry). 
 
 
 
Current Activity in Europe 
In the EBMT database, since 1995, 33,415 MM patients were reported to be in first relapse after 
autologous HCT. In that setting, various salvage treatments were performed: most of the patients, 
26,622 (80%), did not receive a subsequent HCT, 5275 (15.8%) received a subsequent autologous 
HCT (either 1, 4443 [13.3%], 2, 260 [.8%], or a tandem auto followed by allogeneic HCT, 572 
[1.7%]). Another 1527 patients (5%) underwent an allogeneic transplantation at 1 point of their 
treatment course as a salvage therapy. Since 1995, there is a constant increase in the salvage HCT 
numbers, reaching more than 500 patients per year after 2012 (Figure 2A,B). 
 
Figure 2. (A) Since 1995, evolution of salvage treatment after autologous transplantation in 
Europe: no transplantation versus autologous transplantation. 2014 data is incomplete (EBMT 
registry). (B) Since 1995, evolution of salvage autologous transplantation in Europe: single 
(AUTO1) versus double (AUTO2) versus tandem auto-allo (ALLO2). 2014 data is incomplete 
(EBMT registry). 
 
Prospective Trials of Salvage Autologous HCT 
The first prospective randomized trial studying autologous HCT versus less-intensive alkylating 
agent consolidation (weekly cyclophosphamide) after first relapse and reinduction with a 
bortezomib-containing regimen has been reported [42]. This multicenter, randomized, open-label, 
phase III study recruited patients at least 18 years old with MM who needed treatment for first 
progressive or relapsed disease at least 18 months after a previous autologous HCT from 51 centers 
across the United Kingdom. Before randomization, eligible patients received bortezomib, 
doxorubicin, and dexamethasone induction therapy and then underwent peripheral blood stem cell 
mobilization and harvesting, if applicable. Eligible patients (with adequate stem cell harvest) were 
randomly assigned (1:1) to either high-dose melphalan 200 mg/m
2
 plus salvage HCT or to oral 
cyclophosphamide (400 mg/m
2
 per week for 12 weeks). This trial showed a clear advantage in 
terms of time to progression, 19 versus 11 months (P < .0001) for the transplantation arm compared 
with the chemotherapy arm and, in fact, the trial was stopped earlier because it met its predefined 
endpoint. However, the control arm is considered nowadays suboptimal. With limited follow up, an 
OS difference has not been shown. 
The Nordic group published recently a phase II study analyzing salvage autologous HCT in 53 
bortezomib- and lenalidomide-naïve patients who previously received 1 autologous HCT [43]. The 
reinduction was bortezomib based and the conditioning regimen included bortezomib as well. The 
second PFS was similar to the initial PFS, 19 versus 20 months (P = .80). Median OS was almost 
5.5 years with acceptable toxicity [43]. 
Results of Consensus Survey Regarding Role of Autologous 
HCT in Relapsed Myeloma 
Before the consensus conference, participants were asked to rate their agreement with a variety of 
statements regarding salvage HCT, giving a score of 0 if they strongly agreed with the statement 
and a score of 10 if they strongly disagreed. 
When asked if salvage autologous HCT should be considered for all patients relapsing after primary 
therapy, if eligible, and with an initial remission duration of more than 24 months, there was a clear 
consensus agreement (Figure 3A). When asked if salvage autologous HCT should be considered for 
all patients relapsing after primary therapy, if eligible, and with an initial remission duration of less 
than 6 months, there was a clear consensus with most experts strongly disagreeing with that 
approach, as seen in Figure 3B. The degree of agreement was significantly less for patients with 
remissions lasting only 12 to 24 months, as is seen in Figure 3C. 
 
 Figure 3. (A) Expert consensus on role of autologous HCT as consolidation therapy of an initial 
remission after first autograft of greater than 24 months (0 strongly agree and 10 strongly disagree, 
ordinate axis is the number of people who voted). (B) Expert consensus on role of autologous HCT 
as consolidation therapy of an initial remission after first autograft of less than 6 months (0 strongly 
agree and 10 strongly disagree, ordinate axis is the number of people who voted). (C) Expert 
consensus on role of autologous HCT as consolidation therapy of an initial remission after first 
autograft of between 12 and 24 months (0 strongly agree and 10 strongly disagree, ordinate axis is 
the number of people who voted). 
 
Consensus Guidelines for Salvage Autologous HCT 
The consensus committee agreed on the following guideline statements: 
1.In transplantation-eligible patients relapsing after primary therapy that did NOT include an 
autologous HCT, high-dose therapy with autologous HCT as part of salvage therapy should be 
considered standard. 
 
2.High-dose therapy and autologous HCT should be considered appropriate therapy for any patients 
relapsing after primary therapy that includes an autologous HCT with initial remission duration of 
more than 18 months. 
 
3.High-dose therapy and autologous HCT can be used as a bridging strategy to allogeneic HCT. 
 
4.The role of postsalvage HCT maintenance needs to be explored in the context of well-designed 
prospective trials that should include new agents, such as monoclonal antibodies, IMiDs, and oral 
proteasome inhibitors. 
 
5.Autologous HCT consolidation should be explored as a strategy to develop novel conditioning 
regimens or post-HCT strategies in patients with short remission (less than 18 months). 
 
6.Prospective randomized trials need to be performed to define the role of salvage autologous HCT 
in patients with MM relapsing after primary therapy comparing to “best non-HCT” therapy. 
The expert committee also underscored the importance of collecting enough hematopoietic stem 
cells to perform 2 transplantations early in the course of the disease. This is particularly important, 
as 30% of patients in the National Cancer Research Institute (NCRI) Myeloma X Relapse trial 
randomized to second autograft were unable to proceed to HCT because of poor collection. 
Recently, the International Myeloma Working Group wrote guidelines for mobilization, suggesting 
that plerixafor could be used in patients who did not have enough cells collected for a salvage HCT 
as a mobilization strategy [44]. 
Role of Allogeneic HCT as Treatment for Patients Relapsing 
after Primary Therapy Retrospective Studies 
Most studies focusing on transplantation procedures as salvage treatment strategies are separate 
evaluations of either a second salvage autograft or a salvage allograft. Data from comparative 
studies are very few and limited by their retrospective nature and/or their small study populations. 
The largest registry analysis was performed by Freytes et al. using data from the CIBMTR. The 
outcomes of a second autotransplant (n = 137) were compared to those of a salvage allograft (n = 
152) after nonmyeloablative or reduced-intensity conditioning (NST/RIC) from 1995 to 2008. 
Nonrelapse mortality (NRM) at 1 year after transplantation was higher in the NST/RIC cohort, 13% 
versus 2%. Three-year PFS and OS for the NST/RIC cohort were 6% and 20%, respectively, and 
inferior to the outcomes for the autologous transplantation cohort (12% and 46%, respectively) [45]. 
These results contrast with 2 recent donor versus no donor analyses performed in patients relapsing 
after an initial autograft. Patriarca et al. retrospectively analyzed 169 consecutive patients who had 
relapsed after an autograft and had undergone HLA typing immediately after relapse. The 2-year 
NRM was 22% among the 75 patients who had an identified HLA-compatible donor (donor group) 
versus 1% for those without a donor (no donor group). The 2-year PFS was 42% in the donor group 
and 18% in the no-donor group (P < .0001) with similar 2-year OS of 54% and 53% for the donor 
and no donor groups, respectively. Better response did not translate into better OS given a higher 
treatment-related mortality (TRM) in the donor group. An update of this study is eagerly awaited to 
observe possible differences in OS with longer follow up [46]. In another small donor versus no-
donor comparison, de Lavallade et al. showed that patients with relapsed MM and an HLA-identical 
sibling who underwent reduced-intensity allograft had a significantly better event-free survival than 
patients without an HLA-identical sibling (46% versus 8% at 3 years) [47]. A small number of 
single-institution comparison have also been performed and are summarized in Table 4 45, 46, 47, 
48, 49 and 50. 
Table 4. Retrospective Comparisons of Autologous versus Allogeneic HCT for Patients 
Relapsing after an Initial Autograft 
 
 
RR indicates relapse rate; auto, autologous; allo, allogeneic. 
Most reports of allografting as salvage therapy either after first-line autologous transplantation or 
after more lines of therapies have been single-institution or registry analysis and have been 
reviewed extensively elsewhere 51, 52 and 53. All together, these studies showed the feasibility of 
allogeneic transplantation in relapsed MM. However, given the heterogeneous patient cohorts and 
differences in conditioning regimens and supportive care, its real role and curative potential have 
not been clearly established. 
At the recent meeting of the American Society of Hematology in San Francisco (December 2014), 
Michallet et al. presented an EBMT registry study on allografting in MM, which included 7333 
patients who underwent transplantation at a median age of 51 years between January 1990 and 
December 2012. Sixty-four percent of patients underwent transplantation after the year 2004. The 
upfront use of an allograft was observed to gradually decrease after the year 2000 to the current 
12%. Remarkably, an allograft was more frequently used in recent years and, in 2012, most 
allografts, overall 33%, were performed in patients who relapsed after a first autograft. This may 
suggest an overall preference in using an allograft at first relapse after a standard autograft. The 
1588 patients who received an allograft after a single autograft showed 5-year PFS and OS of 26% 
and 33%, respectively, whereas the 930 who received it after failing 2 lines of treatment showed 5-
year PFS and OS of 24% and 29%, respectively, and the 296 who underwent transplantation with an 
allograft after at least 3 lines of treatment showed 5-year PFS and OS of 15% and 23%, respectively 
[54]. This report demonstrates the impact of lines of therapy on allogeneic HCT outcomes, but also 
shows that a small fraction of heavily pretreated patients can achieve long-term disease control with 
allogeneic HCT. 
Prospective Trials 
Published prospective trials on the use of an allograft in the setting of relapsed MM are very few. In 
a prospective multicenter EBMT trial, Kröger et al. investigated the role of allografting from 
unrelated donors in 49 patients who relapsed after a previous autograft. Conditioning regimen 
consisted of melphalan (140 mg/m
2
), fludarabine (90 mg/m
2
), and antithymocyte globulin 
(Fresenius) (60 mg/kg body weight). All patients showed leukocyte and platelet engraftment after a 
median of 15 days and 19 days, respectively. Grades II to IV acute graft-versus-host disease 
(GVHD) occurred in 25%, and 35% of the patients experienced chronic GVHD. The overall 
response rate was 95%, including 46% CR. The cumulative incidence of 1-year TRM was 25% and 
was significantly lower in transplantations from fully HLA-matched donors compared with from 
mismatched donors (10% versus 53%, P = .001). After a median follow-up of 43 months, the 5-year 
PFS and OS were 20% and 26%, respectively, and were significantly better in patients who 
achieved post-transplantation CR (41% versus 7%, P = .04, and 56% versus 16%, P = .02) [55]. 
The introduction of “new drugs” has made allografting a less attractive treatment option because of 
its toxicity, at least in newly diagnosed patients. However, the mechanisms of actions of new drugs 
and immune-mediated graft-versus-myeloma effects are not mutually exclusive. Kroger et al. 
demonstrated that the addition of IMiDs or proteasome inhibitors to donor lymphocyte infusions 
after allogeneic HCT could increase the frequency of CR. Thirty-two patients were treated with 
donor lymphocyte infusions plus either an IMiDs or bortezomib, if no response. Nineteen patients 
achieved CR by EBMT criteria, of which 17 had no evidence of disease by flow cytometric criteria 
and 15 by molecular analysis [56]. Thus, continued exploration of post-transplantation therapies 
with either IMiDs or proteasome inhibitors may demonstrate a definite superiority of allografting as 
salvage therapy. Phase II trials exploring these concepts have already been performed and are 
summarized in Table 5. 
Table 5. Prospective Trials of IMiDS or Proteasome Inhibitors in Allografting 
 
DLI indicates donor lymphocyte infusion; aGVHD, acute graft-versus-host disease; QOD, every other day. 
Kröger et al. investigated a non–total body irradiation myeloablative toxicity-reduced allograft 
consisting of intravenous busulfan (12.2 mg/kg) and cyclophosphamide (120 mg/kg) followed by 
maintenance therapy with lenalidomide in 33 MM patients relapsing after an autograft. Median 
remission duration after the autograft was 12 months. After the allograft, 1-year cumulative 
incidence of TRM was only 6%. Twenty-four patients started maintenance therapy with 
lenalidomide at a median dose of 5 mg for a median of 6 cycles. Cumulative incidence of relapse at 
3 years was 42% and the 3-year estimated probabilities of PFS and OS were 52% and 79%, 
respectively [57]. 
Two other reports have been published regarding the role of post-RIC allogeneic HCT lenalidomide 
maintenance with conflicting results. Kneppers et al. began 10 mg of lenalidomide daily starting 
from 1 month after HCT in 35 patients with MM, of whom 30 were able to take the medication. 
Almost one half of the patients (47%) had to stop the drug after 2 cycles because of the 
development of acute GVHD. Notwithstanding, 37% of patients had a further improvement in their 
MM response and the 1-year PFS from start of maintenance was 69% [58]. Alsina et al. performed 
a multicenter trial to determine the safety and toxicity of maintenance lenalidomide after allogeneic 
HCT. Thirty patients with high-risk MM were enrolled at 8 centers between 2009 and 2012. The 
median time from HCT to initiation of lenalidomide maintenance was 96 days. Eleven patients 
(37%) completed maintenance and 10 mg daily was the most commonly delivered dose (44%). 
Most common reasons for discontinuation were acute GVHD (37%) and disease progression (37%). 
As seen in the German and Dutch trials, acute GVHD was seen in 38% of patients, NRM was 11%, 
with a PFS of 63% at 3 years and an OS of 78% at 3 years [59]. These results demonstrate that 
postallogeneic HCT lenalidomide maintenance is feasible and results in further reduction of MM 
tumor burden; however, whether this results in improved long-term outcomes is uncertain. 
Caballero-Velázquez et al. evaluated bortezomib within a RIC and as maintenance after allografting 
in patients relapsing after a prior autograft. The conditioning consisted of fludarabine (30 mg/m
2
 i.v. 
on days −9 to −5), melphalan (70 mg/m2 i.v. on days −4, −3), and bortezomib (1.3 mg/m2 i.v. on 
day −2); maintenance treatment consisted of cycles of i.v. bortezomib (on days 1, 8, and 15). 
Sixteen patients were prospectively enrolled. Nine of 16 (56%) and 5 of 16 (31%) achieved CR and 
partial remission, respectively. Acute grade III GVHD was observed in 25%. Nonhematological 
toxicities consisted of peripheral neuropathy in 2 patients, liver toxicity in 2, and pulmonary toxicity 
in 1. Three-year cumulative incidences of TRM, relapse, and OS were 25%, 54%, and 41% 
respectively [60]. 
Nishihori et al. explored a similar approach but as consolidation of a first remission. Twenty-two 
MM patients with a very good partial response or better received fludarabine (30 mg/m
2
 i.v. if with 
bortezomib and 40 mg/m
2
 i.v. when without bortezomib, × 4 days) plus melphalan (70 mg/m
2
 i.v. × 
2 days) with (n = 13) or without (n = 9) bortezomib (1.3 mg/m
2
). The risk of moderate to severe 
chronic GVHD at 2 years was 46% but the 2-year PFS was 74.8%, comparing favorably with the 
52% 2-year PFS seen in similar patients who underwent an autologous HCT [61]. 
In the light of these recent findings, 2 large cooperative groups are planning phase II trials 
integrating bortezomib into the conditioning regimens followed by some form of post-
transplantation therapy, including either an IMiD or a proteasome inhibitor. These trials will be 
offered as frontline consolidation therapy of patients with high-risk disease or as consolidation for 
first relapse after an initial autograft. 
There have been no prospective randomized trials of allogeneic versus autologous HCT in the 
relapsed setting. Recently, Gahrton et al. compared outcomes of patients who relapsed on their 
upfront tandem autologous/reduced-intensity allogeneic HCT (auto/RICallo) versus autologous 
HCT. OS after progression was significantly better in the auto/RICallo group than in the autologous 
group (50% versus 27% at 60 months from time of progression). Salvage allograft was performed at 
progression in 11 patients (17%) in the auto/RICallo group and in 17 (8%) in the auto group. At last 
follow-up, a preliminary analysis showed that 3 patients obtained CR and 5 patients were alive; 2 in 
persistent CR in the among patients who received a salvage allograft relapsing after an 
auto/RICallo. Among the 17 patients who received an allograft as salvage of an autograft relapse, 8 
patients obtained CR and 4 patients were alive, all in CR more than 4 years after salvage allogeneic 
HCT. These findings suggest that an allograft is a valid option at progression after either upfront 
auto/RICallo or an autograft [62]. 
Consensus Survey Regarding Role of Allogeneic HCT in 
Relapsed Myeloma 
Before the consensus conference, the attendants were asked to rate their agreement with a variety of 
statements regarding salvage HCT, giving a score of 0 if they strongly agreed with the statement 
and a score of 10 if they strongly disagreed. 
In contrast to the autologous setting, there was much less consensus regarding the role of 
allografting for patients relapsing after autologous HCT, whatever the duration of remission. The 
results of the survey, when asked if salvage allogeneic HCT should be considered for all patients 
relapsing after primary therapy, if eligible, and with an initial remission duration of more than 24 
months, between 12 and 24 months, and less than 6 months, can be seen in Figure 4A-C. 
 
Figure 4. (A) Expert consensus on role of allogeneic HCT as consolidation therapy of an initial 
remission after first autograft of greater than 24 months (0 strongly agree and 10 strongly disagree, 
ordinate axis is the number of people who voted). (B). Expert consensus on role of allogeneic HCT 
as consolidation therapy of an initial remission after first autograft between 12 and 24 months (0 
strongly agree and 10 strongly disagree, ordinate axis is the number of people who voted). (C) 
Expert consensus on role of allogeneic HCT as consolidation therapy of an initial remission after 
first autograft of less than 6 months (0 strongly agree and 10 strongly disagree, ordinate axis is the 
number of people who voted). 
Consensus Guidelines Regarding Role of Allogeneic HCT in 
Relapsed Myeloma 
The expert committee agreed on the following guideline statements: 
1. 
Allogeneic HCT should be considered appropriate therapy for any eligible patient with early 
relapse (less than 24 months) after primary therapy that included an autologous HCT or with 
high-risk features (ie, cytogenetics, extramedullary disease, plasma cell leukemia, or high 
lactate dehydrogenase) provided that they responded favorably to salvage therapy before 
allogeneic HCT. 
2. 
Whenever possible, allogeneic HCT should be performed in the context of a clinical trial. 
3. 
The role of postallogeneic HCT maintenance therapy needs to be further explored. 
4. 
Prospective randomized trials need to be performed to define the role of salvage allogeneic 
HCT in patients with MM relapsing after primary therapy. 
HCT for Patients with Refractory Disease 
The Spanish myeloma group looked at the outcome of outcome of primary refractory MM, which 
they defined as never having achieved a minimal response or better [63]. Patients underwent either 
tandem autologous or autologous HCT followed by RIC allogeneic transplantation. Patients 
progressing under induction therapy had shorter OS from first transplantation than the stable disease 
group. However, induction therapy for all patients did not include any novel agents but was with 
multiagent conventional chemotherapy. In the Mayo series, 50 patients with primary refractory 
MM, defined as failure to achieve a partial response or greater, were compared to 101 patients with 
chemosensitive disease. Twenty percent of the chemorefractory group achieved a CR with the 
transplantation and had a 1-year PFS of 70% [64]. None of these patients received modern day 
therapy with IMiDs and proteasome inhibitors. 
A more contemporaneous analysis from the CIBMTR may be more informative [65]. Five hundred 
ninety-three patients who underwent autologous HCT after failing to achieve less than partial 
remission to first-line induction therapy were identified. The patients were divided into 2 groups: 
those who received additional salvage therapy and those who did not before HCT. On multivariate 
analysis, there was no impact of pretransplantation salvage on TRM, PFS, or OS, thereby 
suggesting that those with suboptimal response to induction could still derive a benefit from high-
dose chemotherapy. 
Knowledge Gaps and Most Compelling Questions 
The expert committee recognized that further randomized trials of the optimal type and timing of 
salvage HCT are essential. Particularly, can patients relapsing after primary therapy be risk 
stratified into high-risks groups, with patients with high-risk disease proceeding to more aggressive 
salvage therapies, including allogeneic HCT, and patients with very low-risk disease continued on 
maintenance therapy without high-dose consolidation? The International Myeloma Working Group 
is currently performing such an analysis and these results will be essential to guide therapy in the 
relapse setting. 
Although recent data suggest that attaining a deep response with primary therapy predicts prolonged 
response before relapse, the impact of depth of response in the salvage setting is less certain. The 
addition of new technologies, such as flow cytometry and deep gene sequencing, now allows for 
monitoring and detection of minimal residual disease. How this information will impact the 
treatment of patients relapsing after primary therapy is still uncertain, but it will likely guide us in 
deciding the intensity of salvage therapies [66]. 
Likewise, the possibility that some cytogenetic or molecular subgroups may not benefit from high-
dose therapy needs to be carefully explored. Pharmacogenomic predictors of response to melphalan 
are currently under investigation [67]. 
As the role of post-transplantation therapy has been well established in the setting of frontline 
autologous HCT, the expert committee recommended that prospective trials exploring optimal 
postsalvage HCT maintenance therapy be considered a priority, particularly those exploring novel 
immunotherapy strategies postsalvage HCT (ie, vaccines, cellular therapies, monoclonal antibodies, 
novel proteasome inhibitors, histone deacetylase [HDAC] inhibitors, and others). With the use of 
prolonged therapy after primary therapy, such as maintenance, it will be critically important to 
investigate novel agents and combinations to overcome resistance to the agent used during 
maintenance (more commonly lenalidomide, bortezomib, or even the combination). Novel 
conditioning regimens should also be explored in this setting. 
Current Protocol Portfolio 
Numerous trials are currently registered on the ClinicalTrials.gov website involving HCT in the 
salvage setting. NCT01745588 aims to compare salvage HCT with pomalidomide/dexamethasone 
and clarithromycin as a maintenance schedule against a non-HCT strategy of pomalidomide, 
clarithromycin, and dexamethasone. NCT01242267 aims to address the augmentation of high-dose 
melphalan with increasing doses of thalidomide in a phase I/II setting. NCT00938626 is aiming to 
utilize Bite antibodies to augment T cell activation before salvage HCT in a phase I/II. The 
Intergroupe Francophone du Myelome is conducting a phase 2 study (NCT02244125) for patients 
in first relapse following the IFM 2009/DFCI trial (VRD [bortezomib (velcade) lenalidomide and 
dexamethasone] induction followed by upfront or delayed HCT followed by a VRD consolidation 
and 1-year lenalidomide maintenance). All patients are treated with the combination of 
pomalidomide plus cyclophosphamide and dexamethasone. The primary endpoint is response after 
4 cycles. If patients are not progressive, they undergo an autologous HCT if they did not get it 
upfront followed by pomalidomide plus cyclophosphamide and dexamethasone consolidation and 
pomalidomide plus dexamethasone maintenance. The German-speaking multiple myeloma study 
group currently enrolls patients in the “RELAPSE” trial, comparing an early versus a late auto HCT 
in patients in patients with 1 to 3 prior therapies (EudraCT 2009-013856-61, ISRCTN 16345835). 
The European Myeloma Network (EMN-alloRIC2010, Eudra-CT number: 2010-018594-37, 
ClinicalTrials.gov Identifier: NCT01460420) has a trial that aims at optimizing clinical outcomes 
by including bortezomib in a melphalan-based conditioning regimen and using a combination of 
bortezomib and lenalidomide as post-transplantation maintenance. Candidates are high-risk 
myeloma patients, younger than 70 years, with early relapse after first primary therapy with new 
drugs and autologous HCT. 
The next NCRI myeloma trial is a randomized trial exploring the role of an augmented melphalan 
conditioning regimen by adding bortezomib followed by a second randomization to either ixazomib 
or placebo for consolidation and maintenance in patients relapsing after an initial autograft. 
The Blood and Marrow Transplant Clinical Trials Network will perform a phase II randomized trial 
of ixazomib maintenance after allogeneic HCT. The conditioning regimen will be melphalan-
bortezomib. Both patients with high-risk myeloma and in first relapse after an autologous HCT will 
be eligible. 
There is an Medical Research Council study that is being developed for relapsed disease after 
primary therapy. 
Conclusions 
Patients with relapsed MM have considerable options for salvage treatment. Randomized trials are 
demonstrating that, as with frontline therapy, depth of response to therapy predicts outcomes. Thus, 
optimal use of high-dose therapy in the salvage setting needs to be extensively explored through 
well-designed prospective trials that include and explore the newly developed agents for MM at 
different phases of the HCT process (induction, conditioning, and maintenance). In the meantime, 
both autologous and allogeneic HCT should be considered valid clinical options based on this 
consensus statement. 
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